Evidence map›Paper›PMID 30348110›Full record

ReviewBMC nephrology2018

The role of klotho in chronic kidney disease.

Di Zou, Wen Wu, Yan He, Sichao Ma, Ji Gao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 7 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 7 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Chronic Kidney Disease and Cellular Senescence.International journal of molecular sciences · 2026
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Di ZouDepartment of Nephrology, The First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, China.
Wen WuDepartment of Medical Ultrasonics, PLA Army General Hospital, Beijing, 100700, China.
Yan HeDepartment of Nephrology, The First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, China.
Sichao MaDepartment of Nephrology, The First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, China.
Ji GaoDepartment of Urology, China-Japan Union Hospital, Jilin University, Changchun, Jilin, 130000, China. gaoji20170729@sina.com.ORCID 0000-0003-2893-2195
The Affiliated Hospital to Changchun University of Chinese Medicine · CNChinese PLA General Hospital · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is an inherently systemic disease that refers to a long-term loss of kidney function. The progression of CKD has repercussions for other organs, leading to many kinds of extrarenal complications. Intensive studies are now being undertaken to reveal the risk factors and pathophysiological mechanism of this disease. During the past 20 years, increasing evidence from clinical and basic studies has indicated that klotho, which was initially known as an anti-aging gene and is mainly expressed in the kidney, is significantly correlated with the development and progression of CKD and its complications. Here, we discuss in detail the role and pathophysiological implications of klotho in ion disorders, the inflammation response, vascular calcification, mineral bone disorders, and renal fibrosis in CKD. Based on the pathogenic mechanism of klotho deficiency and klotho decline in urine early in CKD stage 2 and even earlier in CKD stage 1, it is not difficult to understand that soluble klotho can serve as an early and sensitive marker of CKD. Moreover, the prevention of klotho decline by several mechanisms can attenuate renal injuries, retard CKD progression, ameliorate extrarenal complications, and improve renal function. In this review, we focus on the functions and pathophysiological implications of klotho in CKD and its extrarenal complications as well as its potential applications as a diagnostic and/or prognostic biomarker for CKD and as a novel treatment strategy to improve and decrease the burden of comorbidity in CKD.

Indexed as

Anti-Inflammatory AgentsBiomarkersFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseHumansKlotho ProteinsRenal Insufficiency, ChronicAnti-Inflammatory AgentsBiomarkersFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsChronic kidney diseaseExtrarenal complicationsKlotho functionsPathogenic mechanismPotential applications

Identifiers

PMID30348110
PMCPMC6198535
OpenAlexW2896060548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.